Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. (PLRX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PLRX · as of Sep 30, 2025
Ownership Breakdown
104
Institutional Holders
▼ 12 vs Q2
$74.65M
Total Inst. Value
▲ $14.93M vs Q2
61.92M
Shares Outstanding
freeFloat 97.27%
50.45M
13F Shares Held
▼ 1.04M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PLRX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 6.00M | 9.78% | 9.78% | $8.89B | Nov 14, 2025 | ▲ 3.4K |
WOODLINE PARTNERS LP pharmaceutical preparations | 4.50M | 7.34% | 7.34% | $6.67B | Nov 14, 2025 | ▲ 2.16M |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 4.34M | 7.07% | 7.07% | $6.42B | Nov 14, 2025 | NEW |
MORGAN STANLEY pharmaceutical preparations | 3.51M | 5.71% | 5.71% | $5.19B | May 27, 2026 | ▼ 246.3K |
BLUE OWL CAPITAL HOLDINGS LP pharmaceutical preparations | 2.97M | 4.84% | 4.84% | $4.39B | Nov 12, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 2.78M | 4.52% | 4.52% | $4.11B | Nov 7, 2025 | ▼ 226.4K |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 2.37M | 3.86% | 3.86% | $3.50B | Nov 13, 2025 | ▲ 739.1K |
CITADEL ADVISORS LLC pharmaceutical preparations | 2.34M | 3.81% | 3.81% | $3.46B | Nov 14, 2025 | ▼ 16.4K |
JPMORGAN CHASE & CO pharmaceutical preparations | 2.13M | 3.47% | 3.47% | $3.15B | Nov 26, 2025 | ▲ 172.1K |
REDMILE GROUP, LLC pharmaceutical preparations | 1.59M | 2.59% | 2.59% | $2.36B | Nov 14, 2025 | ▼ 40.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
23
Increased
+6.91M shares5
New Positions
first time holders14
Decreased
−3.23M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.69M
+6.91M / −3.23M
Net new holders
+14
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PLRX insider trading · insider activity
Source: SEC Form 4
20
Buy transactions
20
Sell transactions
1.00
Buy/Sell ratio
$3M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Kuo Minnie Chief Operating Officer | Apr 17, 2026 | Award | 150,000 | $1.33 | $199.5K | 150.0K | Form 4 ↗ |
Kuo Minnie Chief Operating Officer | Apr 17, 2026 | Award | 55,200 | $1.33 | $73.4K | 55.2K | Form 4 ↗ |
Kuo Minnie Chief Operating Officer | Apr 17, 2026 | Award | 40,000 | $1.33 | $53.2K | 40.0K | Form 4 ↗ |
Kuo Minnie Chief Operating Officer | Apr 17, 2026 | D-Return | 150,000 | $16.18 | $2.43M | 0 | Form 4 ↗ |
Kuo Minnie Chief Operating Officer | Apr 17, 2026 | D-Return | 40,000 | $17.44 | $697.6K | 0 | Form 4 ↗ |
Kuo Minnie Chief Operating Officer | Apr 17, 2026 | D-Return | 55,200 | $11.14 | $614.9K | 0 | Form 4 ↗ |
Cummings Keith Lamont Chief Financial Officer | Apr 17, 2026 | Award | 124,000 | $1.33 | $164.9K | 124.0K | Form 4 ↗ |
Cummings Keith Lamont Chief Financial Officer | Apr 17, 2026 | Award | 113,300 | $1.33 | $150.7K | 113.3K | Form 4 ↗ |
Cummings Keith Lamont Chief Financial Officer | Apr 17, 2026 | Award | 110,500 | $1.33 | $147.0K | 110.5K | Form 4 ↗ |
Cummings Keith Lamont Chief Financial Officer | Apr 17, 2026 | Award | 76,200 | $1.33 | $101.3K | 76.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Pliant Therapeutics, Inc. (PLRX) is primarily owned by institutional investors, who hold approximately 81.5% of total shares outstanding. Company insiders own approximately 2.73%, while retail and public investors account for the remaining 15.80%.
The largest institutional shareholder of Pliant Therapeutics, Inc. is TANG CAPITAL MANAGEMENT LLC, holding approximately 6.00 million shares — equal to 9.78% of outstanding shares — as of September 30, 2025.
A total of 104 institutional investors currently hold PLRX stock, with a combined institutional value of approximately $74,654,754 as of the most recent 13F filing period.
Frequently asked questions
PLRX ownershipPliant Therapeutics, Inc. (PLRX) is primarily owned by institutional investors, who hold approximately 81.5% of shares. The largest shareholder is TANG CAPITAL MANAGEMENT LLC with a 9.78% stake. Company insiders hold 2.73%. Data sourced from SEC Form 13F as of September 30, 2025.